Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ABG Oxidative Stress Study Protocol-1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02213523
Recruitment Status : Completed
First Posted : August 11, 2014
Last Update Posted : August 11, 2014
Sponsor:
Information provided by (Responsible Party):
Access Business Group

Brief Summary:
This is a proof of concept study that evaluates the response to oxidative stress in healthy men after taking plant concentrates.

Condition or disease Intervention/treatment Phase
Healthy Dietary Supplement: Plant concentrate A Dietary Supplement: Plant concentrate B Dietary Supplement: Plant concentrate C Dietary Supplement: Plant concentrate D Not Applicable

Detailed Description:

Sustained oxidative stress may cause hypertension, insulin resistance, metabolic syndrome, cardiovascular disease and other chronic conditions. Diets rich in natural antioxidants is associated with protective effects on the investigators health. The strategy to prevent chronic disease development and in making up the nutritional gap in the investigators diet has shifted from vitamins and minerals supplementation to whole foods and whole food products.

The objectives is to evaluate the effect of oxidative stress response of plant concentrate blends. Also, we'll confirm that vitamins, minerals and plant concentrates will not influence the biomarker expression that were monitored in the oxidative stress biomarkers. Lastly, collecting additional information on whether blends of plant concentrate have other potential health benefits.

This study will test the dose-response of blends of plant concentrates. Healthy men (n=60) with low fruit and vegetable intake will participate in a 32 day or 46 days. Each treatment duration lasts 14 days. Microarray assay and real time-polymerase chain reaction will be performed.Genes associated with oxidative stress will me monitored. The outcome of this study will help us understand how to design and develop future antioxidant related products.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Proof of Concept Study to Evaluate the Effect of Oxidative Stress Response of Plant Concentrate Blends in Healthy Men
Study Start Date : September 2012
Actual Primary Completion Date : November 2012
Actual Study Completion Date : December 2013

Arm Intervention/treatment
Experimental: Plant concentrate A
Plant concentrate A containing Rosemary:Quercetin:Turmeric 5:3:1 Low dose (300 mg) to high dose (600 mg)
Dietary Supplement: Plant concentrate A
Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

Experimental: Plant concentrate B
Plant concentrate B containing Holy Basil: Wasabi: Broccoli 5:5:1 Low dose (300 mg) to high dose (600 mg)
Dietary Supplement: Plant concentrate B
Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

Experimental: Plant concentrate C
Plant concentrate C containing Holy Basil:Rosemary:Broccoli seed:Turmeric 2:2:1:1 Low dose (300 mg) to High dose (600 mg)
Dietary Supplement: Plant concentrate C
Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.

Experimental: Plant concentrate D
Plant concentrate D containing Rosemary:Licorice:Turmeric 1:1:1 Low dose (300 mg) to High dose (600 mg)
Dietary Supplement: Plant concentrate D
Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.




Primary Outcome Measures :
  1. Change in urine 8-isoprostane [ Time Frame: Day 1, 15 ]
    Change in antioxidant biomarker from baseline to day 15


Secondary Outcome Measures :
  1. Change in erythrocyte Superoxide Dismutase [ Time Frame: 1, 15 ]
    Change in antioxidant biomarker from baseline to day 15

  2. Change in plasma malondialdehyde [ Time Frame: Day 1, 15 ]
    Change in antioxidant biomarker from baseline to day 15

  3. Plasma hemoxygenase-1 [ Time Frame: Day 1, 15 ]
    Change in antioxidant biomarker from baseline to day 15

  4. Erythrocyte glutathione peroxidase [ Time Frame: Day 1, 15 ]
    Change in antioxidant biomarker from baseline to day 15



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult men between 45-65 yr old with low fruit and vegetable intake
  • Individual with low fruit and vegetable intake and consuming fewer than 12 items found on the Recommended Foods Check (RFC) (AppendixI) per week. (score <12 pts)
  • Individuals with screening blood and urine laboratory values within 20% of normal range indicated in the lab report (Appendix IV)
  • Individual should be judged to be in good general health on the basis of an interview and abbreviated physical exam.
  • Individual understands the procedures and agrees to participate in the study.
  • Individual is willing to maintain their exercise habits and dietary pattern throughout the duration of the trial.
  • Individual is willing to consume a diet or drink devoid of high content of quercetin (e.g. apple and onions), rosemary, turmeric, Holy basil, wasabi, broccoli seeds, and licorice thought the duration of the trial.
  • Individual is able and willing to provide written informed consent and confidentiality agreement.

Exclusion Criteria:

  • Use of dietary supplements within one week of DAy 1. Supplements include any vitamins, minerals, and herbal products, including herbal drink.
  • Presence of, or clinical significant history of, cancer, cardiovascular, endocrine, kidney, liver, lung, gastrointestinal, metabolic disorder, absorption disorder such as Celiae or Crohn's disease and/or any other chronic health condition such as diabetes identified from the finding of the interview.
  • Presence of cardiovascular disease and hypertension with inconsistent medication regimen, unstable conditions, and without proper physician's supervision identified from the findings fo the interview.
  • Individual who use medicines such as statins (e.g. simvastatin, fluvastatin), NSAIDS including aspirin, nitric oxide *eNOS) activators or inhibitors (e.g. selegiline, Viagra), and angiotensin II receptor blocker (e.g. Telmisartan (blood pressure)), and take any of these medications within 10 hours prior to the blood and urine sample collection.
  • Individuals who eat spicy food (e.g. capsaicin from chili pepper) and drink coffee and tea including herbal teas within 10 hours prior to the blood and urine sample collection.
  • Participation in another clinical trial within 30 days of enrollment into the study.
  • History of current abuse of nicotine, drugs or alcohol, or intake >3 alcoholic beverages per day
  • Have known allergy to the ingredients in the tested samples such as quercetin, rosemary, turmeric, Holy basil, wasabi, broccoli seeds, and licorice.
  • Any condition that the principal Investigator believes amy put the subject under risk.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02213523


Locations
Layout table for location information
United States, California
Quality of Life
Buena Park, California, United States, 90620
Southbay Pharma Research
Buena Park, California, United States, 90620
Sponsors and Collaborators
Access Business Group
Investigators
Layout table for investigator information
Principal Investigator: Richard Keech, M.D. Southbay Pharma Research

Layout table for additonal information
Responsible Party: Access Business Group
ClinicalTrials.gov Identifier: NCT02213523     History of Changes
Other Study ID Numbers: ABG AOX-1
First Posted: August 11, 2014    Key Record Dates
Last Update Posted: August 11, 2014
Last Verified: August 2014
Keywords provided by Access Business Group:
antioxidant